Methamphetamine induces cardiomyopathy through GATA4/NF-κB/SASP axis-mediated cellular senescence

Area of Science:

• Cardiovascular Biology
• Toxicology
• Cellular Senescence

Background:

• Methamphetamine (METH) use is a global pandemic, leading to METH-associated cardiomyopathy (MAC), a significant cause of heart failure in young individuals.
• The precise mechanisms underlying MAC development remain unclear, necessitating further investigation into its pathogenesis.

Purpose of the Study:

• To elucidate the molecular mechanisms of METH-induced cardiomyopathy.
• To identify potential therapeutic targets for MAC treatment.

Main Methods:

• Establishment and evaluation of a METH-induced animal model using echocardiography and myocardial pathological staining.
• Analysis of cardiac tissue gene expression via mRNA sequencing.
• Validation of key molecular targets using Western blot, qPCR, and immunofluorescence.
• In vitro studies involving knockdown of GATA4 in H9C2 cells to assess its role in METH-induced senescence.

Main Results:

• The METH-exposed animal model displayed cardiac hypertrophy, fibrosis, systolic dysfunction, and reduced left ventricular ejection fraction (<40%), mirroring clinical MAC.
• Significant upregulation of cellular senescence markers (p16, p21) and senescence-associated secretory phenotype (SASP) was observed in METH-affected myocardial tissue.
• mRNA sequencing identified GATA4 as a key molecule, with its expression significantly increased post-METH exposure.
• Knockdown of GATA4 in vitro effectively reduced METH-induced cardiomyocyte senescence.

Conclusions:

• Methamphetamine induces cardiomyopathy via cellular senescence, critically involving the GATA4/NF-κB/SASP signaling axis.
• Targeting the GATA4/NF-κB/SASP pathway presents a promising therapeutic strategy for managing METH-associated cardiomyopathy.